Pill with 20 on it
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Overview of Oral Contraceptive Pills Containing 20 mcg Ethinylestradiol
Introduction to Low-Dose Oral Contraceptives
Oral contraceptive pills (OCPs) containing 20 micrograms (mcg) of ethinylestradiol have been developed to reduce estrogen-related side effects while maintaining contraceptive efficacy. These low-dose pills are designed to offer a safer profile, particularly for women who may be at risk of estrogen-related complications.
Clinical Efficacy and Cycle Control
Contraceptive Effectiveness
Studies have shown that OCPs containing 20 mcg of ethinylestradiol, combined with various progestins, provide effective contraception. For instance, a clinical trial involving 755 women demonstrated high contraceptive efficacy with good cycle control for a pill containing 20 mcg ethinylestradiol and 100 mcg levonorgestrel. Another study confirmed that these low-dose pills do not compromise contraceptive effectiveness compared to higher-dose pills .
Cycle Control and Bleeding Patterns
Despite their effectiveness, some studies have reported higher rates of early trial discontinuation and increased bleeding disturbances, such as irregular bleeding and spotting, with 20 mcg ethinylestradiol pills compared to those with higher estrogen doses . However, these bleeding patterns can also be influenced by the type of progestin used in the formulation.
Metabolic and Biochemical Effects
Lipid and Lipoprotein Profiles
Research indicates that OCPs containing 20 mcg ethinylestradiol have a favorable impact on lipid and lipoprotein profiles. For example, a study comparing pills with 20 mcg and 30 mcg ethinylestradiol found that both formulations increased high-density lipoprotein cholesterol (HDL-CH) and the HDL-CH/low-density lipoprotein cholesterol (LDL-CH) ratio, which are considered beneficial changes . Additionally, the 20 mcg pill was associated with a significant increase in apolipoproteins AI and AII concentrations.
Glucose and Insulin Levels
The same study observed that the 20 mcg ethinylestradiol pill did not significantly alter fasting insulin and glucose levels or their response to an oral glucose tolerance test (OGTT), suggesting a minimal impact on glucose metabolism.
Safety and Side Effects
Cardiovascular and Hemostatic Effects
The cardiovascular safety of low-dose OCPs is a critical consideration. A study comparing different OCP formulations found that a pill containing 20 mcg ethinylestradiol and 150 mcg desogestrel did not significantly increase fibrinopeptide A (FPA) plasma levels, a marker of coagulation, unlike higher-dose formulations . This suggests a potentially lower risk of thromboembolic events with the 20 mcg pill.
Bone Health
Interestingly, OCPs with 20 mcg ethinylestradiol have been shown to reduce bone resorption markers, similar to higher-dose pills, indicating a protective effect on bone health. This makes them a suitable option for young women concerned about bone density.
Conclusion
Oral contraceptive pills containing 20 mcg ethinylestradiol offer effective contraception with a potentially safer profile due to lower estrogen content. They provide good cycle control and have favorable effects on lipid profiles and bone health. However, they may be associated with higher rates of bleeding disturbances compared to higher-dose pills. Overall, these low-dose pills are a viable option for women seeking effective contraception with reduced estrogen-related side effects.
Sources and full results
Most relevant research papers on this topic